This long-term prospective study shows that injecting cultured human corneal endothelial cells with a ROCK inhibitor provides sustained, 10-year clinical success and safety for patients with corneal endothelial failure. Over a decade of follow-up, the innovative cell therapy effectively maintained corneal transparency, restored cell density, and significantly improved visual acuity with no severe adverse reactions.

Read More »